|
|
Volumn 8, Issue 3, 2002, Pages 199-200
|
|
Set back to Alzheimer vaccine studies
a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALZHEIMER DISEASE VACCINE;
AMYLOID BETA PROTEIN;
ALZHEIMER DISEASE;
AMYLOIDOSIS;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL TRIAL;
COGNITIVE DEFECT;
CONFUSION;
DRUG BINDING;
DRUG MECHANISM;
DRUG SAFETY;
FINANCIAL MANAGEMENT;
HEADACHE;
HUMAN;
IMMUNE RESPONSE;
INFLAMMATION;
INVESTMENT;
LAW SUIT;
MAJOR CLINICAL STUDY;
MICROGLIA;
NOTE;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
T LYMPHOCYTE ACTIVATION;
VACCINATION;
ADJUVANTS, IMMUNOLOGIC;
ALZHEIMER DISEASE;
ALZHEIMER VACCINES;
AMYLOID BETA-PROTEIN;
CLINICAL TRIALS, PHASE II;
DRUG INDUSTRY;
HUMANS;
INFLAMMATION;
INVESTMENTS;
|
|
EID: 0036127580
PISSN: 10788956
EISSN: None
Source Type: Journal
DOI: 10.1038/nm0302-199b Document Type: Note |
|
Times cited : (88)
|
|
References (0)
|